{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:10Z","timestamp":1760189410889,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrrheum.2014.224","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T13:07:49Z","timestamp":1420549669000},"page":"70-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Digging deeper for greater precision and more impact in JIA"],"prefix":"10.1038","volume":"11","author":[{"given":"Berent","family":"Prakken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"BFnrrheum2014224_CR1","doi-asserted-by":"publisher","unstructured":"Wakil, S. M.  et al. Mutation of LACC1 is associated with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. \n                    http:\/\/dx.doi.org\/10.1002\/art.38877\n                    \n                  .","DOI":"10.1002\/art.38877"},{"key":"BFnrrheum2014224_CR2","doi-asserted-by":"publisher","unstructured":"Brunner, H. I.  et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2014-205351\n                    \n                  .","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"BFnrrheum2014224_CR3","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1038\/ncomms5593","volume":"5","author":"T Vogl","year":"2014","unstructured":"Vogl, T.  et al. Alarmin S100A8\/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat. Commun. 5, 4593 (2014).","journal-title":"Nat. Commun."},{"key":"BFnrrheum2014224_CR4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken, B., Albani, S. & Martini, A. Juvenile idiopathic arthritis. Lancet 377, 2138\u20132149 (2011).","journal-title":"Lancet"},{"key":"BFnrrheum2014224_CR5","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/art.27516","volume":"62","author":"S Prahalad","year":"2010","unstructured":"Prahalad, S.  et al. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 62, 2525\u20132529 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014224_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"ED Mellins","year":"2011","unstructured":"Mellins, E. D., Macaubas, C. & Grom, A. A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 7, 416\u2013426 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum2014224_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.berh.2014.05.002","volume":"28","author":"S Vastert","year":"2014","unstructured":"Vastert, S. & Prakken, B. Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 28, 229\u2013246 (2014).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014224_CR8","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell, D.  et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266\u20131273 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum2014224_CR9","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.4049\/jimmunol.1400599","volume":"193","author":"D Bending","year":"2014","unstructured":"Bending, D.  et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J. Immunol. 193, 2699\u20132708 (2014).","journal-title":"J. Immunol."},{"key":"BFnrrheum2014224_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.38223","volume":"66","author":"MH Bromberg","year":"2014","unstructured":"Bromberg, M. H., Connelly, M., Anthony, K. K., Gil, K. M. & Schanberg, L. E. Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. Arthritis Rheumatol. 66, 462\u2013469 (2014).","journal-title":"Arthritis Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.224","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:35:27Z","timestamp":1684470927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrrheum2014224"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.224","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"type":"print","value":"1759-4790"},{"type":"electronic","value":"1759-4804"}],"subject":[],"published":{"date-parts":[[2015,1,6]]},"assertion":[{"value":"6 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.P. has received speaker fees and\/or has served as independent advisor for Amgen, Danone Research and Novo Nordisk. A.M. has in the past 3 years received honoraria and speakers' bureau fees from AstraZeneca, BMS, Boehringer Ingelheim, GSK, MedImmune, Novartis, Novo Nordisk and Sanofi Aventis; the GASLINI Hospital, of which A.M. is a full-time employee, has received support for the research activities of PRINTO from Abbott, AstraZeneca, Bristol\u2013Myers Squibb, Eli Lilly and Company, 'Francesco Angelini' Foundation, GSK, Italfarmaco, Janssen Biologics B.V., Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma and Wyeth Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}